Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Apellis Pharmaceuticals (APLS) Stock Price
Media stories about Apellis Pharmaceuticals (NASDAQ:APLS) have been trending somewhat positive on Friday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.3383339751791 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing Bell (feeds.benzinga.com)
- Busy Year Ahead For OMED, There’s HOPE For GBT, APLS Sinks Below IPO Price (markets.businessinsider.com)
- Apellis Pharmaceuticals Inc (bloomberg.com)
- Apellis Pharmaceuticals, Inc.’s (APLS) Quiet Period Set To End on December 19th (americanbankingnews.com)
- Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with… (culthub.com)
Shares of Apellis Pharmaceuticals (APLS) opened at $13.35 on Friday. Apellis Pharmaceuticals has a 52-week low of $12.45 and a 52-week high of $15.41.
A number of research firms have weighed in on APLS. Evercore ISI began coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They set an “outperform” rating on the stock. J P Morgan Chase & Co began coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They set an “overweight” rating and a $31.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They set a “buy” rating and a $23.00 price target on the stock.
In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $14.00 per share, with a total value of $1,785,210.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Apellis Pharmaceuticals (APLS) Stock Price” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-apellis-pharmaceuticals-apls-stock-price/1764786.html.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.